Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Suxinding sulfate (硫酸舒欣啶) is a small molecule Class III antiarrhythmic agent developed by Hebei Zhongbao Pharmaceutical. Administered via injection, it is specifically designed for the rapid conversion of atrial fibrillation and atrial flutter to normal sinus rhythm. As a Class III antiarrhythmic, its primary mechanism involves the blockade of cardiac potassium channels, which leads to a prolongation of the action potential duration and the effective refractory period in myocardial tissues. This action helps stabilize cardiac rhythm without significantly impacting the conduction velocity of the heart. The drug is currently in Phase 2 clinical development in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on suxinding sulfate.